The most common culprit of alpha-gal, or red meat allergy, is the lone-star tick, which has been steadily expanding out of ...

An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's significantly reduce ...

New phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson's disease, experts ...

Amneal is releasing Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease.

The results of these findings were recently published in Molecular Psychiatry. Treatment of Parkinson's disease is in large part based on the administration of levodopa. The use of this drug is ...

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

Discover Amneal Pharmaceuticals' innovative patent for a controlled release levodopa formulation, enhancing drug delivery without decarboxylase inhibitors.

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today ...

The treatment of Parkinson's disease (PD) focuses on improving symptoms and quality of life. Medication is the hallmark ...

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...